ICON PLC
NASDAQ:ICLR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
187.22
346.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
ICON PLC
ICON PLC
Investor Relations
In the rapidly evolving landscape of global healthcare, ICON PLC stands out as a formidable player, seamlessly bridging the gap between innovative drug development and practical clinical application. Founded in Dublin, Ireland, ICON has grown into a multinational enterprise, deeply embedded in the research and development phases of various medical and biopharmaceutical companies. The company's core strength lies in its ability to offer comprehensive clinical trial services, encompassing every stage of drug development, from initial study design through to final data management and regulatory submissions. ICON's systematic approach not only shortens the timeline for bringing novel therapeutics to market but also ensures that these breakthroughs are both effective and safe, thereby garnering trust from clients ranging from burgeoning biotech startups to pharmaceutical giants.
As a contract research organization (CRO), ICON operates within a business model designed to capitalize on the booming demand for outsourced R&D support. This model involves entering into strategic partnerships with clients to conduct all necessary research activities in exchange for fees, which can be structured through agreements for specific projects or longer-term collaborations. The company leverages its robust network, sophisticated technological platforms, and expert workforce to offer tailored solutions that optimize efficiency and accuracy. By doing so, ICON not only enhances its clients’ product pipelines but also secures a steady stream of revenue, further consolidated through repeat business and the expansion of its service repertoire to include emerging areas like digital health and real-world evidence. This disciplined and innovative approach propels ICON's growth, ensuring its financial health and reaffirming its integral role in driving medical advancement worldwide.
In the rapidly evolving landscape of global healthcare, ICON PLC stands out as a formidable player, seamlessly bridging the gap between innovative drug development and practical clinical application. Founded in Dublin, Ireland, ICON has grown into a multinational enterprise, deeply embedded in the research and development phases of various medical and biopharmaceutical companies. The company's core strength lies in its ability to offer comprehensive clinical trial services, encompassing every stage of drug development, from initial study design through to final data management and regulatory submissions. ICON's systematic approach not only shortens the timeline for bringing novel therapeutics to market but also ensures that these breakthroughs are both effective and safe, thereby garnering trust from clients ranging from burgeoning biotech startups to pharmaceutical giants.
As a contract research organization (CRO), ICON operates within a business model designed to capitalize on the booming demand for outsourced R&D support. This model involves entering into strategic partnerships with clients to conduct all necessary research activities in exchange for fees, which can be structured through agreements for specific projects or longer-term collaborations. The company leverages its robust network, sophisticated technological platforms, and expert workforce to offer tailored solutions that optimize efficiency and accuracy. By doing so, ICON not only enhances its clients’ product pipelines but also secures a steady stream of revenue, further consolidated through repeat business and the expansion of its service repertoire to include emerging areas like digital health and real-world evidence. This disciplined and innovative approach propels ICON's growth, ensuring its financial health and reaffirming its integral role in driving medical advancement worldwide.
You don't have any saved screeners yet
